Treatment-related factors and highly active antiretroviral therapy adherence

被引:54
作者
Trotta, MP
Ammassari, A
Melzi, S
Zaccarelli, M
Ladisa, N
Sighinolfi, L
Mura, MS
D'Arminio Monforte, A
Antinori, A
机构
[1] L Spallanzani IRCCS, Ist Nazl Malattie Infett, I-00149 Rome, Italy
[2] Univ Cattolica Sacro Cuore, Ist Clin Malattie Infett, Rome, Italy
[3] Univ Milan, Ist Malattie Infett & Trop, I-20122 Milan, Italy
[4] Policlin Univ Bari, Clin Malattie Infett, Bari, Italy
[5] Arcispedale St Anna, Div Malattie Infett, Ferrara, Italy
[6] Univ Sassari, Ist Malattie Infett, I-07100 Sassari, Italy
关键词
adherence; HIV/AIDS; antiretroviral therapy; HAART; complexity; side effects;
D O I
10.1097/00126334-200212153-00008
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Adherence to highly active antiretroviral therapy (HAART) plays a critical role in the effectiveness of HIV treatment. Nevertheless, the complexity of regimens and frequent side effects make HAART extraordinarily difficult to take, and many HIV-infected persons fail to adhere. The current study offers an overview of the relationship between adherence and antiretroviral treatment-related variables. As for other chronic diseases, medication regimen complexity also has an impact on adherence in the management of HIV infection. In particular, the authors discuss the effect of pill burden, dosing frequency, dietary instructions, number and type of different medications prescribed, short- and long-term side effects, convenience, and ability to incorporate the treatment regimen into a daily routine. Medication side effects are common in HAART-treated persons and are associated with concurrent and future nonadherence. Simplification of regimens, adjustment of the drug schedule to the patient's specific lifestyle, and anticipation and self-management of side effects are treatment-based strategies to optimize HAART adherence and ensure the most effective, convenient, safe, and well-tolerated antiretroviral treatment.
引用
收藏
页码:S128 / S131
页数:4
相关论文
共 21 条
[1]  
Altice FL, 2001, J ACQ IMMUN DEF SYND, V28, P47, DOI 10.1097/00042560-200109010-00008
[2]  
Ammassari A, 2001, J ACQ IMMUN DEF SYND, V28, P445, DOI 10.1097/00042560-200112150-00006
[3]  
ANTINORI A, 2002, 14 INT AIDS C BARC J
[4]   Antiretroviral therapy adherence and viral suppression in HIV-infected drug users: Comparison of self-report and electronic monitoring [J].
Arnsten, JH ;
Demas, PA ;
Farzadegan, H ;
Grant, RW ;
Gourevitch, MN ;
Chang, CJ ;
Buono, D ;
Eckholdt, H ;
Howard, AA ;
Schoenbaum, EE .
CLINICAL INFECTIOUS DISEASES, 2001, 33 (08) :1417-1423
[5]   Overview of the effectiveness of triple combination therapy in antiretroviral-naive HIV-1 infected adults [J].
Bartlett, JA ;
DeMasi, R ;
Quinn, J ;
Moxham, C ;
Rousseau, F .
AIDS, 2001, 15 (11) :1369-1377
[6]   Self-reported adherence to antiretroviral medications among participants in HIV clinical trials: the AACTG Adherence Instruments [J].
Chesney, MA ;
Ickovics, JR ;
Chambers, DB ;
Gifford, AL ;
Neidig, J ;
Zwickl, B ;
Wu, AW .
AIDS CARE-PSYCHOLOGICAL AND SOCIO-MEDICAL ASPECTS OF AIDS/HIV, 2000, 12 (03) :255-266
[7]   Simplification with abacavir-based triple nucleoside therapy versus continued protease inhibitor-based highly active antiretroviral therapy in HIV-1-infected patients with undetectable plasma HIV-1 RNA [J].
Clumeck, N ;
Goebel, F ;
Rozenbaum, W ;
Gerstoft, J ;
Staszewski, S ;
Montaner, J ;
Johnson, M ;
Gazzard, B ;
Stone, C ;
Athisegaran, R ;
Moore, S .
AIDS, 2001, 15 (12) :1517-1526
[8]  
Duran S, 2001, HIV Clin Trials, V2, P38
[9]   Adherence to antiretroviral and Pneumocystis prophylaxis in HIV disease [J].
Eldred, LJ ;
Wu, AW ;
Chaisson, RE ;
Moore, RD .
JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 1998, 18 (02) :117-125
[10]   Efficacy, safety, and adherence with a twice-daily combination lamivudine/zidovudine tablet formulation, plus a protease inhibitor, in HIV infection [J].
Eron, JJ ;
Yetzer, ES ;
Ruane, PJ ;
Becker, S ;
Sawyerr, GA ;
Fisher, RL ;
Tolson, JM ;
Shaefer, MS .
AIDS, 2000, 14 (06) :671-681